Sulindac. Trials of a new anti-inflammatory drug.
Open Access
- 1 February 1978
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 37 (1), 89-92
- https://doi.org/10.1136/ard.37.1.89
Abstract
Trials in patients with rheumatoid arthritis and osteoarthritis showed sulindac to be an analgesic with anti-inflammatory properties and at least as effective as aspirin. It was effective within 24 hours in doses of 300-400 mg daily. It had the advantages of twice daily administration and a lower incidence of gastric side effects than aspirin. Constipation, usually mild, occurred in 20-30% of cases. Like other anti-inflammatory drugs, it was effective in only a proportion of the patients.This publication has 6 references indexed in Scilit:
- SULINDAC IN OSTEOARTHROSIS OF THE HIPRheumatology, 1976
- [Proceedings: Double-blind comparison of MK 231 with indomethacin in spondylitis ankylopoetica].1975
- Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluro-2-methyl-1-(p-(methylsulfinyl)-benzylidenyl)-indene-3-acetic acid in the rat, dog, rhesus monkey, and man.1973
- CLINICAL STUDIES WITH AN ARTICULAR INDEX FOR THE ASSESSMENT OF JOINT TENDERNESS IN PATIENTS WITH RHEUMATOID ARTHRITISQJM: An International Journal of Medicine, 1968
- Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.1968
- Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis.BMJ, 1967